News

US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults
The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...
FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...
Northwest Asian Weekly3h
Dr. Helen Chu: CDC vaccine panel purge threatens public health
A leading infectious disease expert and one of the nation’s foremost COVID-19 researchers has voiced deep concerns about the ...
US CDC official in charge of COVID, RSV data resigns ahead of vaccine meeting
A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...
Clinical Advisor1d
RSV Vaccine mResvia Approved for Adults Aged 18 to 59 at Increased Risk
For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.
STAT5d
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...
Kennedy's picks for vaccine advisory panel raise concerns about anti-vaccine bias
A few of the new members Health Secretary Robert F. Kennedy Jr. appointed to the federal panel have promoted misinformation about vaccines and public health.